InvestWiser

Photocure

PHOOslo BørsHealthcareMarket value 1.1 bn NOK
41.70NOK +3.2%
last day · Price as of 18 November 2026

The answer first

Does Photocure beat the market?

No, Photocure has not beaten the market over the last year.

Photocure−29.6%Oslo Børs (OSEBX)+29.5%
  • The ranking · Quality, value and trend combined

    Better than 26% of Nordic stocks

    • Quality51
    • Value51
    • Trend16

    No. 114 of 195 in healthcare

  • Expectations in the price

    Moderate expectations

    For the share to return about 9% a year from today's price, the cash Photocure keeps must grow about 6% a year for 10 years.

Max for seven days

Follow Photocure with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Photocure

From today, at a price of 41.70 NOK. Write why you follow Photocure, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Photocure

Your first answer is free, no account needed.

Do you own Photocure, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Photocure and a few more. Free, no card.

Past year against the exchange and Super Stock
Photocure−29.6%Oslo Børs (OSEBX)+29.5%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Photocure has fallen 29.6% over the past year, including dividends.
  • Overall, Photocure ranks better than 26% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 67.6%. The price is 72.4% below its peak now.

What do analysts think of Photocure?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

26

Quality, value and trend together. Better than 26% of Nordic stocks.

No. 114 of 195 in healthcare

Quality51
The company · Fundamentals: the accounts

Medium An average company: the accounts are neither especially strong nor weak.

No. 128 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.19
  • Asset turnoverSales divided by everything the company owns0.78
  • Return on equityProfit divided by equity+8.3%
  • Cash conversionOperating cash flow divided by profit1.70

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value51
The price · Valuation: the multiples

Medium Fair price: about the same as a typical Nordic stock.

No. 50 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity1.9
  • P/SPrice divided by sales1.6
  • P/EPrice divided by earnings22.9
  • P/CFPrice divided by operating cash flow13.5

The ranking is built on P/E, P/B and P/S.

Trend16
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 139 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−22.9%
  • 6 months−36.7%
  • 9 months−33.4%
  • 12 months−29.6%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−16.8%
3 years, per year
−7.7%
5 years, per year
−18.8%
10 years, per year
+1.2%
Largest fall, 3 years
−67.6%
From a peak to the bottom
From the peak now
−72.4%
How far the price is from the peak
Volatility, 1 year
41.5%
How much the price swings over a year
Beta, 1 year
−0.26
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Photocure

7 funds we follow own Photocure. The share is how much of the fund the stock makes up.

  • Norway5
  • Sweden2

From the funds' latest known holdings.

About Photocure

Photocure is a company in healthcare, listed on Oslo Børs. The share trades in NOK. It has around 99 employees.

Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Cevira, a photodynamic drug-device combination product candidate for the non-surgical treatment of high-grade cervical dysplasia.

See the full analysis of Photocure.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Oslo Børs

Explore the stock market